Sugi Predict

Sugi Predict / Compounds / SCHEMBL1775116

SCHEMBL1775116

SCHEMBL1775116

CC(C)(F)[C@H]1COCc2nc3c(N)nc4cc(OCc5ccccc5)ccc4c3n21

nearest known ligand 0.36

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TLR7 Q9NYK1 8/20 0.36
▸ PARP14 Q460N5 1/20 0.36
▸ TLR8 Q9NR97 3/20 0.35
▸ AR P10275 1/20 0.35
▸ NUDT1 P36639 1/20 0.34
▸ CYP3A4 P08684 3/20 0.34
▸ ALOX5 P09917 1/20 0.34
▸ DYRK1A Q13627 1/20 0.34
▸ GRM5 P41594 3/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1774146 0.87 PARP14 (0.39) TLR7PARP14CYP3A4DYRK1AGRM5
SCHEMBL1775134 0.85 PARP14 (0.37) TLR7PARP14CYP3A4DYRK1AGRM5
SCHEMBL4702126 0.85 PARP14 (0.37) TLR7PARP14CYP3A4DYRK1AGRM5
SCHEMBL1775024 0.84 TLR7 (0.43) TLR7TLR8NUDT1
SCHEMBL10237196 0.84 TLR7 (0.43) TLR7TLR8NUDT1
SCHEMBL1775140 0.82 TLR7 (0.39) TLR7TLR8NUDT1ALDH1A1HPGD
SCHEMBL10237173 0.81 CYP3A4 (0.39) TLR7CYP3A4GRM5KDM4EALDH1A1
SCHEMBL1773836 0.81 CYP3A4 (0.39) TLR7CYP3A4GRM5KDM4EALDH1A1
SCHEMBL1774906 0.79 CYP3A4 (0.37) CYP3A4GRM5KDM4EALDH1A1CYP1A2
SCHEMBL311081 0.77 PRKDC (0.43) PARP14CYP3A4GRM5ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546383-B2 Chiral fused [1,2]imidazo[4,5-c] ring compounds 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-10-01 — — US disclosed
US-20120232057-A1 CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS 3M INNOVATIVE PROPERTIES COMPANY 2012-09-13 — — US disclosed
EP-1831226-B1 CHIRAL TETRACYCLIC COMPOUNDS INDUCING INTERFERON BIOSYNTHESIS 3M INNOVATIVE PROPERTIES CO (US) 2012-08-08 — — EP disclosed
US-8207162-B2 Chiral fused [1,2]imidazo[4,5-c] ring compounds 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-06-26 — — US disclosed
US-20110207725-A1 CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS 3M INNOVATIVE PROPERTIES COMPANY 2011-08-25 — — US disclosed
US-7943609-B2 Such as (tetrahydr)imidazo(4,5-c ) quinoline or naphthymidine; immunomoderators; induce cytokine biosynthesis in animals; anticancer agents; viricides 3M INNOVATIVE PROPRERTIES COMPANY (US) 2011-05-17 — — US disclosed
US-20080269192-A1 Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-10-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269192-A1 Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds IFNAR1, IFNG, IL4 TLR7 124/4885PARP14 3412/4885TLR8 409/4885
US-20120232057-A1 CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS IFNAR1, IFNG, IL4 TLR7 132/4885PARP14 3425/4885TLR8 440/4885
US-20110207725-A1 CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS IFNAR1, IFNG, IL4 TLR7 124/4885PARP14 3412/4885TLR8 409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.